Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Eli Lilly reports 94% Lp(a) reduction with lepodisiran in Phase 2 trials, targeting inherited heart disease risk.

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Eli Lilly's lepodisiran met Phase 2 trial goals, significantly lowering Lp(a) levels. A Phase 3 study is enrolling to assess ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...

Eli Lilly is developing a groundbreaking drug, lepodisiran, to combat high LPA cholesterol levels prevalent in South Asians, ...

In this photo illustration, the injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April ...

Eli Lilly has reported promising Phase II results for lepodisiran, its experimental therapy aimed at reducing lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.

Eli Lilly (LLY) and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

Lilly's lepodisiran shows a 94% reduction in heart disease risk by lowering lipoprotein(a) levels, offering a breakthrough in cardiovascular innovation.